Furthermore, both the percentage and absolute number of CD14+HLA-DR−/low cells prior to therapy negatively correlated with the clinical response and PFS following cisplatin-based chemotherapy in advanced NSCLC patients, suggesting that increased levels of immunosuppressive CD14+HLA-DR−/low cells might be associated with the poor prognosis of NSCLC. Here, CD14 is linked to non-small cell lung carcinoma.